Insilico Medicine vs PathAI

Insilico Medicine has a disclosed valuation of $1.2B, while PathAI's valuation is not publicly available, making a direct size comparison difficult. Insilico Medicine employs 350 people.

Insilico Medicine has raised more in total funding at $403M, compared to PathAI's $255M — a gap of $148M. Combined, the two companies have completed 6 known funding rounds.

Insilico Medicine holds the higher Awaira Score at 67/100, compared to PathAI's 62/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 5-point gap that reflects meaningful differences in scale or traction.

Insilico Medicine was founded by Alex Zhavoronkov in 2014. PathAI was founded by Andy Beck in 2016. Visit each company's profile on Awaira for a full founder biography.

Insilico Medicine: Insilico Medicine is an AI-driven drug discovery and development company founded in 2014 and headquartered in the USA. The company leverages artificial intelligence, machine learning, and generative models to accelerate the identification and optimization of drug candidates across multiple therapeutic areas. Its core platform integrates physics-based modeling with deep learning to predict molecular properties, identify disease targets, and design novel compounds with improved efficacy and reduced toxicity. The company operates across several segments: AI-powered target identification, lead optimization, and clinical trial optimization. Notable applications include oncology, aging-related diseases, and fibrosis. Insilico Medicine has demonstrated its technology through partnerships with pharmaceutical companies and biotech firms seeking to reduce drug development timelines and costs. The platform has been applied to various disease targets, with some candidates advancing through development stages. With $403 million in total funding and a valuation of $1.2 billion, Insilico Medicine represents a significant player in the AI healthcare sector. The company went public, reflecting investor confidence in its technology platform and business model. Its competitive position centers on the integration of generative AI models with molecular biology expertise. The company competes alongside other AI drug discovery platforms while differentiating through its aging research focus and established pharma partnerships. Insilico Medicine uniquely combines generative AI with longevity research, targeting age-related diseases while maintaining traditional pharma collaboration channels. PathAI: PathAI is an AI healthcare company founded in 2016 that develops digital pathology solutions and AI-powered diagnostic tools for pathology labs and healthcare institutions. The company specializes in machine learning algorithms designed to assist pathologists in analyzing tissue samples and identifying diseases, particularly cancer. PathAI's core technology platform leverages deep learning and computer vision to process histopathology images, enhancing diagnostic accuracy and workflow efficiency. The company's primary offering includes software that integrates with existing laboratory information systems, enabling pathologists to use AI-assisted analysis for specimen evaluation. PathAI has developed partnerships with major healthcare systems and diagnostic laboratories, demonstrating clinical utility in oncology and other pathology specialties. The platform addresses critical challenges in pathology including diagnostic consistency, workload management, and access to specialized expertise in underserved regions. PathAI has raised $255 million in total funding as of its Series C stage, with valuation not disclosed. The company operates in the competitive digital pathology and AI diagnostics space, alongside competitors offering similar computational pathology solutions. The digital pathology market is experiencing significant growth driven by increasing diagnostic demands, laboratory automation trends, and regulatory acceptance of AI-assisted tools. PathAI's trajectory reflects broader momentum in AI-enabled healthcare diagnostics and precision medicine applications. PathAI combines deep learning with pathology workflows to create clinically integrated AI tools that assist rather than replace human pathologists.

Insilico Medicine was founded first in 2014, giving it 2 years of additional market experience. PathAI was founded later in 2016. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Insilico Medicine has approximately 350 employees, while PathAI has approximately 300. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Insilico Medicine and PathAI are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.